Vijaya Diagnostic Centre Ltd Q4 FY2024 Concall Summary

Key Takeaways

• 28% YoY revenue growth, 18.5% organic: Q4 was driven by volume growth of 17% and footfall growth of 15%, with both radiology and pathology segments contributing.
• Margins held at 40.7% despite expansion: The integrated B2C model and strong top line absorbed the costs of organic and inorganic expansion, including the PH acquisition which did not dilute margins.
• PH integration is on track: Co-branding is complete, IT systems are migrated, and the ₹114 crores goodwill is not at risk of impairment even before new hubs open.
• A 10-hub, 2-year expansion plan is now explicit: Capex of ₹200-220 crores will be funded entirely from internal accruals, with a focus on Pune and the East.
• What to watch next quarter: The pace of new hub openings in Pune, the breakeven timeline for the Kolkata hub, and whether the core business can sustain 40% margins as the expansion cycle accelerates.

The PH Acquisition: Integration, Accounting & Growth Plan

• Co-branding and IT migration done: PH has been rebranded as "Vijaya PH" and its core ERP was migrated to the parent's systems effective April 1, 2024, marking the operational integration as complete.
• Goodwill is not a near-term risk: The ₹114 crores goodwill from the ₹147.5 crores purchase price allocation is supported by a ₹45-48 crores revenue run rate at 40% EBITDA margin from just the existing 3 hubs and 3 spokes, so no impairment is expected even without expansion.
• Existing PH network is at capacity: The legacy 6-centre network has reached full utilization and will grow only in single digits for the next 1-2 years until new hubs open and existing centres are decluttered.
• New hubs are the growth engine: Management expects to add 5 hubs in Pune over the next couple of years, which should at least triple PH's current revenue to ₹135-150 crores in 4-5 years.
• New hub breakeven is fast: New PH hubs are expected to breakeven within 1 year, potentially taking one extra quarter because the PH brand is already known in the market.

Narasimha Raju: "So without even further expansion, the goodwill is not going to be impacted to P&L by this impairment. But on top of that, what we're planning is we're trying to add 5 hubs, in the next couple of years. And so what I expect is that in the next 4 to 5 years, I see this revenue of INR45 to INR50 crores should at least triple the current number."

Expansion Strategy: Hubs, Capex & Geography

• 10 hubs in 2 years, fully funded: The company has clear visibility on 10 hub centres and a few spokes, with 6-7 leases already signed; the ₹200-220 crores capex will be covered by a ₹185 crore treasury and ₹170-190 crores in annual free cash flow.
• Pune is the priority market: About 5 of the 10 planned hubs will be in Pune, including one flagship facility with PET CT and gamma camera; management expects faster initial growth in Pune than Hyderabad due to fewer integrated diagnostic chains.
• East and core geographies follow: Beyond Pune, expansion will focus on the East (2 hubs in Kolkata already operational) and existing core markets in Andhra and Telangana.
• Existing network also gets investment: A second MRI machine is planned for a Tier 2 hub where footfall is around 300 patients, adding capacity within the mature network.
• Inorganic appetite is selective and Southern: Management is open to inorganic opportunities, with core interest down South towards the East; Mumbai would be considered if the right opportunity appears, but nothing up North is on the radar.
• Debt is only for M&A: No debt is needed for the 2-year organic capex plan; the balance sheet would only be levered for an inorganic acquisition.

Sunil Chandra: "Inorganic is always a question mark. So I think what I can only say is that if we find suitable opportunities, we will look at them. And the balance sheet supports us, I think."

Margin Outlook: Core Stability, Expansion-Led Dilution

• Core margins are anchored at 40%: Management is confident of sustaining 40% EBITDA margins in the core business, supported by the integrated B2C model's cost structure and a strategy of driving volume over price.
• Expansion will dilute margins by 1-2%: The 10-hub plan, with each hub reaching breakeven in 2-3 quarters, is expected to create a manageable ~1% impact on overall EBITDA margin, with some commentary suggesting up to 2%.
• PH margins are already at parity: The acquired PH business is operating at margins similar to Vijaya's, so the acquisition itself is not a dilutive force as new hubs ramp.
• Pricing stays disciplined: The founder's vision of affordable pricing means only 1-2% price hikes are taken on the overall test menu, and only if vendor input costs rise significantly; growth is engineered through volume and new customer acquisition.

Suprita Reddy: "We normally -- like we said, the founder's vision was trying to keep prices affordable and get growth through volume and new customers. Until and unless, we see a significant increase in price and input costs, we do not pass it on to the customers."

Operational Execution: New Hub Performance & Customer Experience

• Mahabubnagar hub breakeven in 2 quarters: The first new hub outside core markets completed 6 months of operations and achieved breakeven within 2 quarters, validating the hub rollout model.
• Kolkata showing promise: Month-on-month performance has been very promising, with breakeven anticipated within the next 2 months; the disease case mix differs from core markets, with more gastro, body imaging, and liver work.
• Gulbarga on a 3-quarter breakeven track: Having completed 1 quarter, the Gulbarga hub is expected to breakeven in the next 2 quarters.
• Customer experience metrics are improving: A new digital app and e-commerce website were launched; TAT for routine pathology is now under 6 hours, and 85% of MRI/CT reports are released within 3 hours, up from 75% in FY20.
• Operational pace is gated by talent, not capital: The company increased hub additions from 4-5 per year to a 10-hub target over 2 years, but the binding constraint is finding and training skilled manpower, since 70% of operations run on skilled staff.

Suprita Reddy: "It's also finding the right talent with the right wavelength, right, Girish. It's skilled manpower. 70% of our ops run on skilled manpower. As we speak, we do different things. That's also the reason why we do a lot of skill development programs and all that. But building that is not as easy as probably we speak."

Volume & Wellness: The Growth Drivers

• Volume is the primary growth lever: Of the 15% organic growth target, roughly 12-13% is expected to come from volumes, with only 1-2% from price and case mix impact.
• Wellness contribution is rising: The wellness segment improved by nearly 200 bps this quarter, driven by both PH's higher wellness mix and an increase in the base wellness business in Hyderabad, Andhra, and Telangana; company-level wellness mix now stands at 14%.
• Footfall growth of 15% underpins revenue: Q4's 17% volume growth was supported by a 15% increase in footfall, with both employee health checks and B2C walk-ins contributing.

Guidance & Commitments

Key Metrics